| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.13 | 0.009 |
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | -0.089 | 0.01 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | -0.084 | 0.01 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | -0.078 | 0.01 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | -0.081 | 0.01 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.085 | 0.01 |
| mRNA | lovastatin | CTRPv2 | pan-cancer | AAC | -0.085 | 0.02 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.02 |
| mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | -0.082 | 0.02 |
| mRNA | navitoclax:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.08 | 0.03 |